Skip to main content
Tessa NewsLink
Paste a health news link, or browse

Source study found

Story checked

Schneider Shorts 16.10.2026 – A comprehensive, fully manual, line-by-line review of the entire manuscript – For Better Science (opens in a new tab)

Schneider Shorts 16.10.2026 – A comprehensive, fully manual, line-by-line review of the entire manuscript · 2026-10-16

Short answerEvidenceSource

Short answer

Mostly not supported

Mostly not supported.

5 key claims are not backed by the study. One other point was not covered by the paper.

  • 1 supported
  • 5 not supported
  • 1 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1

The story

Schneider Shorts 16.10.2026 – A comprehensive, fully manual, line-by-line review of the entire manuscript – For Better Science

Schneider Shorts 16.10.2026 – A comprehensive, fully manual, line-by-line review of the entire manuscript · 2026-10-16

The story’s checkable claims.

Read the original story (opens in a new tab)
2

NewsLink checks it

Mostly not supported

Five claims aren't supported by the study. One of seven checks out. One claim the study doesn't address.

  • 1 supported
  • 5 not supported
  • 1 not covered
Open claim evidence
3
Source paper

Source layer

The 25 papers the story cites

Source study separated from background citations.

The research anchor for the report.

Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

7 claims in this story

Showing all 7 claimsChoose a verdict to focus the list.

Claim 1 of 7Not supportedA Gels correction for a review by Portuguese authors and a Tunisian coauthor was a "comprehensive, fully manual, line-by-line review of the entire manuscript" that removed and replaced many citations, while the authors said no changes were made to text, figures, tables, scientific interpretations, results, or conclusions.View evidenceHide evidence

As stated69 references at the end of the correction

Why this verdict

The supplied paper profile is for the MIT/Nature Biotechnology NK-cell lipid-nanoparticle paper and contains no evidence about a Gels correction, Portuguese/Tunisian authors, or citation replacements. This external research-integrity claim is outside the supplied paper evidence.

Claim 2 of 7Not supportedAn Inorganics review on perovskite materials was retracted because a significant number of references were judged inappropriate or invalid in context, undermining the publication's reliability, though the authors disagreed with the decision.View evidenceHide evidence

Why this verdict

The supplied paper profile contains no evidence about an Inorganics perovskite-materials review or a retraction based on inappropriate references. This claim is not supported by the provided MIT/Nature Biotechnology paper profile.

Claim 3 of 7Not supportedA 2023 Environmental Research paper on zinc ferrite nanoparticles for diclofenac wastewater remediation was retracted after PubPeer concerns about backtracking in UV-Vis spectra and inconsistent Tauc-plot band gaps; the authors did not supply raw data.View evidenceHide evidence

Why this verdict

The supplied paper profile contains no evidence about a 2023 Environmental Research diclofenac-remediation paper, PubPeer UV-Vis/Tauc-plot concerns, or missing raw data. The claim is outside the evidence in the provided paper profile.

Claim 4 of 7Not supportedA Biological Psychiatry paper on 5-lipoxygenase and Alzheimer's tau pathology was retracted after an institutional investigation determined blot data had been reused in later publications and source data were unavailable for verification.View evidenceHide evidence

Why this verdict

The supplied paper profile contains no evidence about a Biological Psychiatry paper on 5-lipoxygenase, Alzheimer's tau pathology, blot reuse, or institutional-investigation findings. The claim is unsupported relative to the provided paper evidence.

Claim 5 of 7Not supportedA Magnetochemistry paper on oxygen-hyperstoichiometric titanium-substituted strontium ferrite nanoparticles was retracted after Texas A&M University informed the journal of an institutional investigation that questioned the integrity of the XRD data in Figure 1.View evidenceHide evidence

Why this verdict

The supplied paper profile contains no evidence about a Magnetochemistry strontium ferrite nanoparticle paper, Texas A&M communications, or questioned XRD data. This claim is outside the supplied paper evidence.

Claim 6 of 7Not coveredThe underlying paper identified for the MIT work is Nature Biotechnology 2026, "In vivo engineering of CAR natural killer cells for immunotherapy using ligand-directed lipid nanoparticles."View evidenceHide evidence

Why this verdict

The supplied profile's scientific content matches the described topic of in vivo CAR NK engineering using ligand-directed lipid nanoparticles, but the profile does not provide bibliographic metadata sufficient to verify the exact journal, year, or title as stated. This is therefore not verifiable from the abstract-depth profile alone.

Claim 7 of 7SupportedThe article presents MIT researchers Daniel Anderson and Robert Langer as having developed an in vivo CAR NK-cell engineering approach using ligand-directed lipid nanoparticles, which the story describes as an example of nano delivery systems and says may help target lymphoma and autoimmune disease.View evidenceHide evidence

Why this verdict

At abstract depth, the profile supports the core scientific framing: the paper develops ligand-directed NK-targeted lipid nanoparticles for in vivo mRNA delivery, uses them to generate CAR NK cells in vivo, reports activity against autoreactive T cells in a murine autoimmune hepatitis model, and reports regression in humanized hematologic malignancy models. The story's broad 'may help' disease framing is consistent with preclinical evidence. However, author identities, the press-release quote, and the specific label 'lymphoma' are not independently verified in the supplied abstract profile.

1

Study evidence

Lead NK-targeted LNPs (NtLNPs) using engineered biparatopic NK ligands achieve high, NK-selective in vivo mRNA transfection in mice, reported up to ~80% of NK cells, with minimal reported off-target effects.~80% NK cell transfection (reported, mice)

“we develop NK cell-targeted LNPs (NtLNPs) using engineered biparatopic NK cell ligands to drive receptor-specific uptake and mRNA delivery.”
2

Study evidence

Systemic NtLNP delivery of CAR mRNA generates CAR-expressing NK cells in vivo in mice.

“Systemic delivery of chimeric antigen receptor (CAR) mRNA using NtLNPs generates CAR NK cells in vivo.”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • Systemic NtLNP delivery of CAR mRNA generates CAR NK cells in vivo; CD19-targeted CAR NKs completely deplete circulating B cells in healthy mice.

    The story broadly mentions in vivo CAR NK engineering and cancer/autoimmune targeting, but the distinct healthy-mouse CD19 CAR pharmacodynamic result—complete circulating B-cell depletion—is not reflected.

    From in_vivo_animal

  • NtLNPs targeting the inhibitory checkpoint NKG2A enhance antitumor efficacy in solid tumor models by relieving Qa-1b-mediated immunosuppression.

    The story's highlighted science section focuses on CAR NK engineering for lymphoma/autoimmune applications and does not mention the separate NKG2A checkpoint-modulation solid-tumor result.

    From in vivo animal

3 things the story did carry across
  • Development of NK-cell-targeted, ligand-directed lipid nanoparticles using engineered biparatopic NK-cell ligands for receptor-specific in vivo mRNA delivery, with reported high NK-selective transfection in mice and minimal off-target effects.
  • CD3-targeted CAR NK cells generated by NtLNP delivery eliminate nearly all autoreactive T cells in a murine autoimmune hepatitis model.
  • Optimization of NtLNPs for in vivo engineering of human CAR NK cells, enabling regression of two humanized hematologic malignancy models.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

5

Evidence read

study summary

Lead result

in vivo animal

1Lead resultin vivo animalDevelop and characterize NK cell–targeted ligand-directed lipid nanoparticles (NtLNPs) that achieve high, NK-selective in vivo mRNA delivery in mice.in vivo animal LNP targetingExpand

In plain English

The authors report development of NK cell–targeted lipid nanoparticles (NtLNPs) that use engineered biparatopic NK-cell ligands to direct receptor-specific uptake and deliver mRNA in vivo. Lead formulations achieve high, NK-selective transfection in mice (reported up to ~80% of NK cells) with minimal reported off-target expression, establishing a platform for generating CAR-expressing NK cells in vivo.

Key findings

  • Lead NK-targeted LNPs (NtLNPs) using engineered biparatopic NK ligands achieve high, NK-selective in vivo mRNA transfection in mice, reported up to ~80% of NK cells, with minimal reported off-target effects.~80% NK cell transfection (reported, mice)
“we develop NK cell-targeted LNPs (NtLNPs) using engineered biparatopic NK cell ligands to drive receptor-specific uptake and mRNA delivery.”
What this piece can’t prove
  • Performance claims are reported for mice; abstract does not provide the detailed in vivo validation data necessary to evaluate generalizability or translational relevance.

2 further details could not be confirmed from the summary.

2in vivo animalDemonstrate therapeutic in vivo programming of CAR NK cells via NtLNP delivery of CAR mRNA in murine models (B-cell depletion; autoimmune hepatitis model).in vivo animalExpand

In plain English

Systemic delivery of CAR mRNA using NK-targeted lipid nanoparticles (NtLNPs) generates CAR-expressing NK cells in vivo in mice; CD19-directed CAR NK cells produced via this approach cause complete depletion of circulating B cells in healthy mice, with minimal reported off-target effects.

Key findings

  • Systemic NtLNP delivery of CAR mRNA generates CAR-expressing NK cells in vivo in mice.
  • CD19-targeted CAR NK cells generated in vivo by NtLNPs completely deplete circulating B cells in healthy mice.Complete depletion (reported)
“Systemic delivery of chimeric antigen receptor (CAR) mRNA using NtLNPs generates CAR NK cells in vivo.”
What this piece can’t prove
  • Abstract does not provide detailed information on dosing, timing, durability of CAR expression, or safety/toxicity endpoints.

2 further details could not be confirmed from the summary.

3in vivo animalDemonstrate therapeutic in vivo programming of CAR NK cells via NtLNP delivery of CAR mRNA in murine models (B-cell depletion; autoimmune hepatitis model).Expand

In plain English

The authors report that systemic delivery of CD3-targeted CAR mRNA using NK cell-targeted lipid nanoparticles (NtLNPs) generates CAR NK cells in vivo in a murine autoimmune hepatitis model and that these CD3 CAR NKs 'eliminate nearly all autoreactive T cells.'

Key findings

  • In a murine autoimmune hepatitis model, systemic NtLNP delivery of CD3-targeted CAR mRNA generated CAR NK cells in vivo and the CD3 CAR NKs 'eliminate nearly all autoreactive T cells' (abstract).Elimination of nearly all autoreactive T cells (as stated in abstract).
“CD3-targeted CAR NKs eliminate nearly all autoreactive T cells in an autoimmune hepatitis model”
What this piece can’t prove

3 further details could not be confirmed from the summary.

4in vivo animalUse NtLNPs to modulate NK inhibitory checkpoint signaling (NKG2A targeting) to enhance antitumor efficacy in solid tumors.Expand

In plain English

The abstract reports that systemic delivery of NK-targeted lipid nanoparticles (NtLNPs) designed to engage the inhibitory checkpoint NKG2A relieves Qa-1b–mediated immunosuppression in mouse solid tumor models and thereby enhances antitumor efficacy in vivo.

Key findings

  • NtLNPs targeting the inhibitory checkpoint NKG2A enhanced antitumor efficacy in solid tumor models by relieving Qa-1b–mediated immunosuppression.
“In solid tumors, NtLNPs targeting the inhibitory checkpoint NKG2A enhance antitumor efficacy by relieving Qa-1b-mediated immunosuppression.”
What this piece can’t prove

3 further details could not be confirmed from the summary.

5in vivo animalOptimize NtLNPs for in vivo engineering of human CAR NK cells and demonstrate efficacy in humanized hematologic malignancy models.in vivo animalExpand

In plain English

The authors report optimization of NK-targeted lipid nanoparticles (NtLNPs) for in vivo engineering of human CAR-expressing NK cells and show that systemic delivery of human CAR mRNA using these optimized NtLNPs leads to regression of two humanized hematologic malignancy models in vivo (humanized mice).

Key findings

  • Optimized NtLNPs enable in vivo engineering of human CAR NK cells, and systemic delivery of human CAR mRNA with these NtLNPs produces regression of two humanized hematologic malignancy models.
“Lastly, we optimized NtLNPs for in vivo engineering of human CAR NK cells, enabling regression of two humanized hematologic malignancy models”
What this piece can’t prove
  • Findings derive from humanized mouse models (preclinical in vivo), which may not fully predict outcomes in human patients.

1 further detail could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

Crossref, PubMed, Europe PMC · 39 candidate papers

Candidate

RETRACTED: A Comprehensive Review of Recent Advances in Perovskite Materials: Electrical, Dielectric, and Magnetic Properties

Inorganics · 2025 · Crossref

Source (opens in a new tab)
Candidate

Influence of graphene loading and temperature on the dielectric response and relaxation dynamics of GE/P(VDF-TrFE) nanocomposites

Materials Research Bulletin · 2026 · Crossref

Source (opens in a new tab)

And 33 more candidates considered.